Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

I spent four crazy years writing about Cassava Sciences. Yesterday, the story ended exactly as I and many others knew it ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...

Italian researchers have developed a nasal spray showing promise in slowing Alzheimer's progression. Tests on mice with ...